These therapeutic mAbs are highly effective at treating blood tumoral disease in patients with Sézary syndrome (SS; also known as leukemic CTCL, L-CTCL), with anti-CCR4-mAb treatment showing increased efficacy in patients with high blood tumor burden15. Here, CCR4 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.